about us

Becoming a global biotech company

Sylus is a biotech company specializing in peptides as a INNOPOLIS Research Institute Spin-off Company,
which was jointly established in April 2019 by Samyoung Unitech and Daegu Gyeongbuk Institute of Science and Technology.

Currently, we are focusing on the development of EPOR-targeted ischemic stroke treatment using EPO-derived peptides,
and plan to expand indications to treat neurodegenerative diseases such as dementia in the future.

We are also planning to enter the health & beauty market utilizing the outstanding efficacy and safety of peptides.

With a passion for your health and happiness, we want to help you create a future you love.
Kyung-il Jung. CEO & Founder, Sylus

go to samyoung unitech home page →

contact

Thank you for visiting the Sylus homepage.